Generics

In September 2022, we launched Lenalidomide Capsules, a therapeutic equivalent generic version of REVLIMID® (lenalidomide) Capsules approved by U. S. Food and Drug Administration (USFDA). With this volume-limited launch, we became eligible for first-to-market, 180 days of generic drug exclusivity for Dr. Reddy’s Lenalidomide Capsules in 2.5 mg and 20 mg strengths.
Our growth in North America in FY’24 was largely on account of increased volumes in the base business, including Lenalidomide as well as revenues from new products launched in FY2024. With patients at our core, in 2023 December we entered into an exclusive collaboration with Coya Therapeutics, Inc. for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS). Read more about this here. We acquired a leading women’s health and dietary supplements portfolio, MenoLabs®. We collaborated with Mark Cuban Cost Plus Drug Company, aimed at increasing access to essential medications for Wilson disease patients. We launched 20 new products, including Treprostinil Injection, Regadenoson Injection in the U.S. as well as products acquired from Mayne Pharma and filed 17 new Abbreviated New Drug Applications (ANDAs) with the US Food and Drug Administration (USFDA).
For selected drugs in our portfolio, we offer patient support services. We also partner with specialty pharmacies to unlock the potential of our complex and injectable generics in the growing specialty drug segment. One of the most recent ones being patient support services for Dr. Reddy’s Sapropterin Dihydrochloride. The services included a patient hub, co-pay assistance, benefits/reimbursement liaison, and nutrition and nursing support.
In addition, we have also launched our own digital marketplace for the institutional segment, DrReddysDirect.com. 

We have been present in the North American region, comprising the USA and Canada, since the mid-1990s. It is our biggest business, with revenue in FY’22 touching a historical milestone of $1 billion, and the revenue for FY’24 closing at approximately $1.6 billion. Our portfolio covers over 230 products across the retail, institutional, and over-the-counter (OTC) segments.\n\nOur pipeline includes several first-to-market drugs and complex products across drug-device combinations, peptides, and long-acting injectables.

We currently serve patients in over 14 European countries with our portfolio of generic and biosimilar medicines and OTC products across various therapeutic categories.

As healthcare challenges rise globally, we remain committed to increasing access to affordable medicines and developing products to serve unmet needs. Our generic medications are identical to approved brand-name drugs but are often available at a fraction of the cost — providing essential savings to healthcare systems and patients.

While we continue accelerating access in Europe, we have expanded our reach for consumer healthcare products by launching the anti-hay fever medicine Histallay® as an OTC product, making it available to patients faster. Our bevacizumab biosimilar received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. Another essential addition to our portfolio is the drug-free migraine management wearable, Nerivio®, currently available in Germany, Spain, and the UK.

In addition to Dr. Reddy’s Laboratories, we operate through our German subsidiaries betapharm and Nimbus Health GmbH (Nimbus Health). While betapharm is a trusted brand for generics and OTC medicines, Nimbus Health is a licensed pharmaceutical wholesaler focused on medical cannabis. Medical cannabis is increasingly used to address and treat unmet medical needs, particularly in pain management and central nervous system (CNS) disorders. As more European countries adopt the usage of medical cannabis, Nimbus Health will expand into additional geographies.

As part of our growth strategy for Europe, we will continue to explore both organic and inorganic opportunities. A recent example is our signed definitive agreement with Haleon plc, a leading consumer healthcare company, to acquire shares of Northstar Switzerland SARL — a Haleon group company — and take over Haleon’s global portfolio of consumer healthcare brands in the Nicotine Replacement Therapy (NRT) category outside of the United States.

This portfolio includes Nicotinell, a global leader in the NRT category with a strong presence in over 30 countries across Europe, Asia (including Japan), and Latin America. It also includes local market-leading brand names such as Nicabate in Australia, Thrive in Canada, and Habitrol in New Zealand and Canada. The proposed acquisition covers all formats — including lozenge, patch, gum, and pipeline products — across all applicable global markets outside of the U.S.